(1/2) A very exciting milestone for ⁦@VolastraTx⁩ and the field of #Chromosomal_Instability. Early escalation data for our KIF18A inhibitor, VLS-1488, show excellent safety and promising efficacy in heavily pre-treated ovarian cancer patients.

Our Spatial Genome Organisation 2025 attendees! Some fantastic presentations, discussions and collaborations have taken place over the past 2 days, with plenty more to come. Its been a pleasure working with Karim, Irene and Matthias on this meeting, looking forward to what the

🧬It was great to speak with @Samuel_Bakhoum at #ESMO25, who shared fascinating insights into how chromosomal instability creates therapeutic vulnerabilities in cancer, its potential to guide treatment selection, and the most promising strategies to exploit this hallmark of

USA needs regulatory reform faster, especially decentralized IRB approval of first-in-man trials. That is how China will win, if we do not correct this glaring, self-imposed bureaucratic error.

🚨 This year’s @NobelPrize is awarded for the important discovery of #Tregs but it’s also a great testament for how seminal and impactful scientific breakthroughs can happen in #biotech (eg. Brunkow and Ramsdell) building on academic insight.

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

🚨👇Excellent thread by @mittallab on our recent collaborative study linking EZH2 to abnormal #mitosis and #Chromosomal_Instability. To our knowledge EZH2 inhibitors are the first known drugs to suppress #CIN in #cancer https://t.co/ZGaHZ8fwTK

Now online in @CD_AACR: Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase - by Yang Bai, @Samuel_Bakhoum, @mittallab, and colleagues https://t.co/no8n3BGJET @WeillCornell

Excited to participate in the upcoming #Chromosomal_Instability session at #ESMO25 @myESMO alongside valued colleagues in the field. Great to see growing interest in targeting this hallmark of cancer for therapeutic benefit. Feel free to reach out if you’re interested in #CIN!

📢Deadline extended! Our 2nd Spatial Genome Organisation Conference deadline has been extended to 25 Sep, dont miss out on joining our fantastic line up of speakers, alongside Karim, Matthias and Irene in what is set to be a fantastic meeting this October! #SGO25 Final slots

Hi @Samuel_Bakhoum we are looking forward to your presentation at the #SGO25 🇲🇽 Please share this with your followers to let them know the poster and registration deadline is fast approaching - Monday 01 September! Register now ➡️ https://t.co/fG3QWAd7Is

A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy | Science

Thanks so much for hosting me I had a great visit and getting to know about the exciting science taking place at the CNIO

Provider Taxes: The Most Elegant Grift in American Healthcare It’s not a tax. It’s a laundering operation. Here’s how it works: 1. A health system “voluntarily” agrees to a provider tax because it loves paying taxes. 2. The state uses that “tax” to inflate Medicaid spending

@KarimMekhail @altmeyerlab @RogerRogergr @JumanaAHA @efapostolou29 @Samuel_Bakhoum @tonycesare4 @CatherineFreud2 @taekjip @brokendna @LeungLab @PeterLyLab Please share with your followers! @NucleomeHunter @Kramadan2 @jesstylerlab @CreminsLab @MarinaLusic

Want to better understand nuclear and genome organisation in various organisms, tissues, and cell states? Join @KarimMekhail , @altmeyerlab & Irene Chiolo at the upcoming 2nd Spatial Genome Organisation Conference this October! Talk Submission has been extended until 14th July,

Dr. Phuoc Tran kicking off a session on #Chromosomal_Instability at the #Prostate #Cancer #Foundation ⁦@PCFnews⁩ #Coffey_Holden Amazing science 🧬 and great speakers. It’s great to see a recognition for this important cancer driver by the PCF and others

This will grab headlines but they used the ChatGPT 4 model which is for basic reasoning, which I would not consider tumor board to fit this. The o3 model actually reasons and would be at least a fighting chance. I have put it to the test with very complex scenarios with

Early findings from a first-in-human trial of VLS-1488, an oral KIF18A inhibitor, show promising anti-tumor activity in heavily treated ovarian cancer. No dose-limiting toxicities were observed. Presented by Dr. Ecaterina Dumbrava at #ASCO25. #EndCancer

The U.S. doesn’t just spend more on healthcare — it drowns in its own bureaucracy. And much of that burden? Created and enforced by government regulation. Compared to other developed countries, the U.S. system is structurally unique — and not in a good way. 🔹 Government-Driven

Absolutely thrilled to welcome David Southwell as ⁦⁦@VolastraTx⁩ new CEO! David’s brings extensive biotech experience and strategic vision that will be instrumental in advancing our KIF18A program and discovery pipeline. Welcome to the team David!